R

RA Capital Management

Invests in healthcare, life sciences.

Healthcare Associate

Full-Time
$150k - $170k+ Performance-based bonus
Junior, Mid
PhD, MD
Boston, MA, USA
HybridMust be based in the Greater Boston area and commute to the Boston office on a hybrid schedule.
Finance & BankingVenture Capital
No H1B Sponsorship

About the job

Requirements
  • Rapidly learn and assimilate information about new science and therapeutic areas.
  • Critically analyze preclinical and clinical data and draw conclusions about its strength and implications.
  • Have experience leveraging AI in a project or work environment.
  • Convey clear and concise ideas through written and oral communication, including investment theses, pitch decks, and presentations.
  • Manage multiple business requirements and deadlines, and proactively communicate when additional support is needed.
  • Be authorized to work in the United States without sponsorship.
  • Have a PhD in the biological sciences or an MD degree.
  • Have 2–5 years of experience in consulting, investment banking, fund work, or related experience.
  • Be willing to be based in the Greater Boston area and commute to the Boston office on a hybrid schedule.
Responsibilities
  • Develop expertise in several therapeutic areas and/or technologies.
  • Meet with biotech and life science companies to evaluate investment opportunities.
  • Analyze and communicate the significance of preclinical and clinical data sets.
  • Conduct due diligence with Investment Team members and inform investment decisions using knowledge of the current standard of care, unmet needs, and therapies in development in areas of coverage.
  • Communicate analyses, conclusions, and recommendations in written and oral forms.
  • Work with portfolio companies on strategy, pipeline prioritization, and other topics as needed.
  • Interview and survey key opinion leaders and subject matter experts.
  • Attend scientific and investor conferences.
  • Maintain in-depth knowledge of competitive landscapes in coverage areas.
  • Create and update competitive landscapes in therapeutic coverage areas using RA Capital’s proprietary mapping system.
  • Assess inbound investment opportunities and make initial recommendations to the team.

About the company

RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.

Company Size

N/A

Company Stage

N/A

Total Funding

$41B

Headquarters

Boston, Massachusetts

Founded

2001

Get referred to RA Capital Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • RA Capital led Tyra's $400 million September 2026 offering, showing deep syndicate influence.
  • September 2026 rounds for Solstice Oncology, Tectora, and Typewriter confirm active deal access.
  • AbbVie's June 2026 acquisition of Apogee and 2024 Aliada validate exit generation.

What critics are saying

  • Yale won a July 24, 2026 jury verdict against RA Capital for trade secret theft.
  • August 24, 2026 judgment formalized a $4 million award and contract breach finding.
  • A growing September 2026 financing binge increases exposure if multiple portfolio bets miss clinical endpoints.

What makes RA Capital Management unique

  • Peter Kolchinsky's team combines biotech diligence with multi-stage capital across private and public markets.
  • RA Capital financed 70 approved drugs and backed 125 IPOs through 2026.
  • Its 200-plus person platform adds structured capital, company creation, and commercialization support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Company News

Morningstar
Oct 21st, 2026
Optivolt raises $32M to embed power electronics "brain" in solar panels

Optivolt, a San Francisco power electronics company, has raised a $32 million Series A led by VXI Capital. RA Capital, Valo Ventures, and Atlas Innovate also took part, bringing its total funding to $42 million. The company's Power Balancer puts active electronics inside a solar panel. It shifts energy among cell groups in real time to recover power lost to shade, weather, dirt, and uneven wear. More than 20,000 panels with the technology have shipped. Optivolt will use the money to expand manufacturing and bring the product to systems from homes to utility-scale projects. In internal tests, panels with the technology produced up to six times as much power as those with bolted-on optimizers under defined shade scenarios.

Business Wire
Oct 13th, 2026
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

Lake Oconee Breeze
Sep 30th, 2026
Sagimet Biosciences prices $115M stock offering for Phase 3 acne trial and denifanstat pre-launch

Sagimet Biosciences has priced an underwritten offering of $115 million in Series A common stock and pre-funded warrants. The clinical-stage biopharmaceutical company will sell 8,750,010 shares at $10.00 per share, along with pre-funded warrants to purchase 2,750,010 shares at $9.9999 each. Commodore Capital is leading the financing, with participation from RA Capital Management, Spruce Street Capital, BVF Partners, and other institutional investors. The offering is expected to close on 1 October 2026. Sagimet plans to use the proceeds to fund a Phase 3 clinical trial for denifanstat in acne, pre-launch activities, advance its TVB-3567 programme through Phase 2, and support general corporate purposes. The company develops novel therapeutics targeting dysfunctional metabolic and fibrotic pathways.

Business Wire
Sep 17th, 2026
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C fundin...

Business Wire
Sep 16th, 2026
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and ...